Novocure Reports Second Quarter 2019 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novocure (NVCR) Tops Q2 EPS by 6c, Revenues Beat
July 25, 2019 6:16 AM EDTNovocure (NASDAQ: NVCR) reported Q2 EPS of ($0.01), $0.06 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $86.7 million versus the consensus estimate of $80.24 million.
Quarterly net revenues of $86.7 million, representing 41 percent growth versus the second quarter 2018The NovoTTF-100L System FDA approved to treat malignant pleural mesothelioma in combination with standard chemotherapies, Novocures first FDA-approved torso... More